Financial Performance - The net profit attributable to the parent company for 2022 was RMB 307.72 million, with the parent company achieving a net profit of RMB 298.78 million[5]. - The proposed cash dividend distribution is RMB 3.13 per 10 shares, totaling RMB 120.06 million, which accounts for 39.02% of the net profit attributable to shareholders[6]. - The company reported a significant increase in revenue, reaching RMB 1.2 billion in 2022, representing a growth of 15% compared to the previous year[22]. - The company achieved operating revenue of ¥1,201,604,254.24 in 2022, representing a year-on-year growth of 8.43%[25]. - Net profit attributable to shareholders decreased by 4.54% to ¥307,719,145.65, while the net profit after deducting non-recurring gains and losses fell by 10.88% to ¥274,208,661.74[25]. - The net cash flow from operating activities was ¥41,007,526.40, a significant decline of 75.11% compared to the previous year[25]. - Basic and diluted earnings per share were both ¥0.80, reflecting a decrease of 13.98% year-on-year[24]. - The gross margin improved to 45% in 2022, up from 42% in 2021, reflecting better cost management and pricing strategies[22]. Research and Development - The company has invested RMB 50 million in R&D for innovative medical technologies, aiming to improve product offerings and patient outcomes[22]. - The company's R&D investment as a percentage of operating revenue increased to 13.51%, up by 4.05 percentage points from the previous year[24]. - The company reported a total R&D investment of approximately ¥162.34 million in 2022, a 54.84% increase from the previous year, representing 13.51% of total revenue[114]. - The number of R&D personnel increased to 399, representing 30.62% of the total workforce, up from 27.39% in the previous year[122]. - The average salary of R&D personnel rose to 12.41 million RMB, compared to 12.28 million RMB in the previous year[122]. - The company is focusing on R&D of new materials such as porous tantalum, magnesium alloy, and PEEK to enhance its product offerings[34]. - The company is actively pursuing innovation in emerging technologies, with ongoing research and development efforts in various new medical materials[81]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[22]. - A strategic acquisition of a local competitor is in progress, which is anticipated to increase production capacity by 30%[22]. - The company plans to enhance its distribution network, aiming for a 15% increase in distribution points by the end of 2023[22]. - The company is actively expanding into overseas markets, which may be affected by international political and economic changes[134]. - The company is expanding its product offerings in sports medicine and dental fields, with new registrations for various medical devices, indicating a comprehensive approach to market expansion[110]. Product Development - New product development includes the launch of a next-generation orthopedic implant, expected to enhance market competitiveness and drive sales growth[22]. - The company is developing customized orthopedic implants, with several products in various stages of regulatory approval, including artificial ligaments and personalized hip and knee implants[118]. - The company is developing advanced customized joint prosthetics using China's national skeletal database and 3D reconstruction technology, which has a broader application range compared to existing customized products[79]. - The company has made significant progress in the development of 3D printing technologies for orthopedic implants, enhancing product quality and production efficiency[126]. - The company is in the design phase for a series of new biomedical materials, indicating a strong commitment to expanding its product offerings in the medical device market[81]. Corporate Governance - The board of directors consists of 8 members, including 3 independent non-executive directors, and held 15 meetings during the reporting period[184]. - The supervisory board is composed of 3 members, with at least one-third being employee representatives, and held 6 meetings during the reporting period[185]. - The company maintains independence in finance, personnel, assets, business, and organization, ensuring a complete business system and autonomous operational capability[186]. - The company has established a robust internal information disclosure management system, adhering to principles of truthfulness, accuracy, completeness, timeliness, and fairness[187]. - The company held its first A-share and H-share class shareholder meetings in 2022, approving various resolutions including the appointment of financial auditing institutions and the remuneration of directors[190]. Challenges and Risks - The company has outlined potential risks in its operations, which are detailed in the report[4]. - The company faced challenges from the "volume-based procurement" policy, leading to a decrease in product selling prices[25]. - The implementation of national "volume-based procurement" has led to a decrease in product prices, significantly squeezing profit margins[130]. - The company faced risks related to reliance on a single overseas supplier for core materials, which could impact production if supply is disrupted[129]. Financial Health - The company's cash and cash equivalents at the end of the reporting period amounted to ¥957.19 million, representing 28.07% of total assets, a decrease of 44.88% compared to the previous period[158]. - Accounts receivable increased by 22.13% to ¥488.75 million, accounting for 14.33% of total assets, primarily due to an expansion in sales scale[158]. - Inventory rose by 62.70% to ¥259.79 million, representing 7.62% of total assets, as the company increased product stock in response to market demand[158]. - The company’s accounts payable rose by 66.97% to ¥237.79 million, indicating an increase in business payables[158]. - The company’s tax payable increased by 65.78% to ¥53.55 million, attributed to the growth in business operations[158].

证券代码：688236 证券简称：春立医疗 公告编号：2023-007 北京市春立正达医疗器械股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 3 月 24 日(星期五)至 2023 年 03 月 30 日(星期四)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@clzd.com 进行提 问。公司将在说明会上对投资者普遍关注的问题进行回答。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）将于 2022 年 3 月 31 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成 果、财务状况，公司计划于 2023 年 03 月 31 日上午 10:00-11:30 举行 2022 年度业绩暨 现金分红说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2022 年度经营成果及财 务指标的具 ...

Financial Performance - The company's operating revenue for Q3 2022 was ¥188,572,691.83, representing a decrease of 20.02% compared to the same period last year[8]. - Net profit attributable to shareholders for Q3 2022 was ¥52,725,036.03, an increase of 8.44% year-on-year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 46.80% to ¥24,953,166.18 in Q3 2022[8]. - Total operating revenue for Q3 2022 was CNY 759,964,308.26, an increase from CNY 718,393,295.82 in Q3 2021, representing a growth of approximately 5.4%[38]. - Net profit for Q3 2022 reached CNY 209,707,532.63, compared to CNY 204,175,210.23 in Q3 2021, reflecting a slight increase of approximately 2.5%[41]. - The total comprehensive income for the period was CNY 209,707,532.63, compared to CNY 204,175,210.23 in the same period last year, reflecting an increase of approximately 2.5%[43]. - Basic and diluted earnings per share were both CNY 0.55, down from CNY 0.59 in the previous year, indicating a decrease of about 6.8%[43]. Research and Development - Research and development expenses totaled ¥32,724,564.79 in Q3 2022, accounting for 17.35% of operating revenue, an increase of 4.22 percentage points year-on-year[11]. - Research and development expenses for Q3 2022 amounted to CNY 105,014,400.73, significantly higher than CNY 65,183,009.37 in Q3 2021, marking an increase of around 61.1%[38]. - The company emphasized increased investment in R&D to address performance pressure and slow growth due to centralized procurement[16]. - The company aims to enhance its market share and competitiveness through continuous R&D investment and expansion of market channels[16]. Assets and Liabilities - Total assets at the end of Q3 2022 were ¥3,109,675,551.59, reflecting a 3.67% increase from the end of the previous year[11]. - The total assets as of Q3 2022 were CNY 3,109,675,551.59, compared to CNY 2,999,657,361.45 in Q3 2021, showing an increase of approximately 3.7%[34]. - Total liabilities for Q3 2022 were CNY 487,987,384.89, down from CNY 530,579,974.97 in Q3 2021, indicating a decrease of about 8.0%[34]. - The company's equity attributable to shareholders increased to CNY 2,621,688,166.70 in Q3 2022 from CNY 2,469,077,386.48 in Q3 2021, representing a growth of approximately 6.2%[34]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥76,368,941.72, a significant decline of 231.72%[11]. - Cash inflow from operating activities totaled CNY 675,604,729.35, an increase from CNY 635,612,963.26, representing a growth of approximately 6.3%[46]. - Cash outflow from operating activities was CNY 751,973,671.07, compared to CNY 577,635,870.48 in the previous year, showing an increase of about 30%[46]. - The net cash flow from operating activities was negative at CNY -76,368,941.72, contrasting with a positive CNY 57,977,092.78 in the same period last year[46]. - Cash inflow from investment activities was CNY 1,550,365,527.41, significantly higher than CNY 6,786,876.71 in the previous year[46]. - The net cash flow from investment activities was CNY -534,949,975.29, worsening from CNY -176,539,833.18 in the previous year[46]. - Cash outflow from financing activities was CNY 58,832,013.62, compared to CNY 1,685,045.25 in the previous year, indicating a substantial increase[46]. Shareholder Information - The total number of A-share shareholders at the end of the reporting period was 17,101, while H-share shareholders numbered 18[24]. - The number of shares held by the top ten shareholders accounted for a significant portion of the total shares, with the largest shareholder holding 29.88%[20]. - The total number of shares held by HKSCC NOMINEES LIMITED was 94,680,695, representing a substantial foreign investment presence[20]. Strategic Focus - The company aims to enhance its market share as a leading orthopedic enterprise by actively responding to national policies and expanding its marketing network[25]. - The company is focused on strategic layout for future growth, emphasizing the importance of tracking market dynamics and enhancing operational efficiency[25]. - The company plans to continue investing in new product development and market expansion strategies to drive future growth[41].

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[19] - The company's revenue for the first half of 2022 was approximately ¥571.39 million, representing an increase of 18.39% compared to ¥482.63 million in the same period last year[28] - Net profit attributable to shareholders was approximately ¥156.98 million, a slight increase of 0.92% from ¥155.56 million year-on-year[28] - The company achieved a revenue of 571.39 million yuan in the first half of 2022, representing a year-on-year growth of 18.39%[140] - Net profit attributable to shareholders was 156.98 million yuan, with a year-on-year growth of 0.92%, while the net profit excluding non-recurring items increased by 8.55% to 156.66 million yuan[142] Research and Development - The company is investing RMB 50 million in R&D for advanced medical technologies, focusing on minimally invasive surgical devices[19] - The R&D expenditure accounted for 12.65% of the revenue, an increase of 5.56 percentage points compared to 7.09% in the same period last year[32] - The company's R&D expenses surged by 111.19% to CNY 72.29 million, reflecting a strong focus on new product and technology development[159] - The company has increased its R&D personnel to 281, representing 23.28% of the total workforce, up from 21.78% in the previous year[132] - The average salary for R&D personnel has risen to CNY 6.76 million, compared to CNY 6.18 million in the previous year[134] Market Expansion and Product Development - The company plans to launch three new orthopedic products by the end of 2022, targeting a market expansion of 30% in the orthopedic device sector[19] - Future guidance estimates a revenue growth of 25% for the second half of 2022, driven by increased demand and new product launches[19] - Market expansion efforts include entering two new provinces in China, aiming for a 10% market share in those regions by 2023[19] - The company is focused on the continuous development and research of orthopedic medical devices, which are critical in the healthcare sector[38] - The company is expanding its market presence through the development of new products and technologies[44] Strategic Acquisitions and Partnerships - The company has completed a strategic acquisition of a local competitor, which is expected to enhance its market position and increase revenue by 15%[19] - The company has established partnerships with three major hospitals to improve product distribution and increase brand visibility[19] - The company is also exploring mergers and acquisitions to enhance its market position and product portfolio[44] Operational Efficiency - The management highlighted a focus on enhancing supply chain efficiency, which is projected to reduce costs by 5% in the next fiscal year[19] - The company has implemented a comprehensive procurement strategy, focusing on raw materials, energy, and external processing services to support efficient operations[85] - The production model is aligned with strategic planning and market demand, ensuring annual supply capabilities while maintaining safety stock levels[88] Risks and Challenges - The company is facing risks related to reliance on a single foreign supplier for core materials, which could impact production if supply is disrupted[147] - The company is adapting to changes in sales models due to policies like "two-invoice system" and "volume-based procurement," which may affect revenue distribution[144] - The company is facing risks from national procurement policies that may lead to price reductions and lower gross margins[149] - The company is closely monitoring the impact of macroeconomic factors, including the ongoing COVID-19 pandemic and international political changes, on its business operations[153] Product Offerings - The company is a leading domestic orthopedic medical device manufacturer, focusing on the research, production, and sales of implantable orthopedic medical devices[44] - Main product categories include joint prosthetics, spinal implants, and sports medicine products, covering various human joints such as hip, knee, shoulder, and elbow[45] - The company offers a full range of spinal internal fixation systems as part of its spinal implant product line[44] - The company's sports medicine products include non-absorbable suture anchors and titanium plates, designed for soft tissue repair in various joints[81] Financial Position - The company's total assets at the end of the reporting period were approximately ¥3.11 billion, an increase of 3.58% from ¥2.99 billion at the end of the previous year[28] - The accounts receivable balance at the end of the reporting period was 603.22 million yuan, an increase of 20.30 million yuan from the beginning of the period, indicating potential credit risk[148] - Inventory rose to ¥182.32 million, reflecting a 14.18% increase from ¥159.68 million, driven by product stockpiling based on market demand[162] Sustainability and Corporate Governance - The company has implemented energy-saving measures, including geothermal heat pump air conditioning and solar power generation at its new production base, indicating significant future energy savings[196] - The company implemented measures to reduce carbon emissions, including promoting paper-saving practices and green commuting among employees[197] - The company does not plan to distribute profits or increase capital reserves, with no dividends or stock bonuses proposed for the reporting period[192]

Financial Performance - The company's revenue for Q1 2022 was ¥257,113,202.13, representing a year-on-year increase of 13.45%[6] - Net profit attributable to shareholders was ¥74,021,366.53, reflecting an 8.09% increase compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥74,435,071.03, up by 10.05% year-on-year[6] - Total operating revenue for Q1 2022 was 257,113,202.13, an increase from 226,624,200.07 in Q1 2021, representing a growth of approximately 13.3%[32] - Net profit for Q1 2022 reached 74,021,366.53, compared to 68,481,917.59 in Q1 2021, reflecting a growth of approximately 8.5%[35] - The company reported a total comprehensive income of 74,021,366.53 for Q1 2022, compared to 68,481,917.59 in Q1 2021, reflecting an increase of approximately 8.5%[35] Research and Development - Research and development expenses totaled ¥33,114,231.75, marking a significant increase of 124.70%[9] - R&D expenses accounted for 12.88% of total revenue, an increase of 6.38 percentage points compared to the previous year[9] - Research and development expenses in Q1 2022 amounted to 33,114,231.75, significantly higher than 14,736,953.37 in Q1 2021, marking an increase of about 125%[32] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥3,040,149,651.90, a 1.35% increase from the end of the previous year[9] - Total current assets as of March 31, 2022, amounted to approximately CNY 2.48 billion, an increase from CNY 2.45 billion as of December 31, 2021, reflecting a growth of about 1%[24] - Total assets reached CNY 3.04 billion, up from CNY 2.99 billion, indicating an increase of approximately 1%[27] - Total liabilities included accounts payable of CNY 100.62 million, down from CNY 142.42 million, a decrease of about 29%[27] - Total liabilities decreased from 530,579,974.97 to 497,050,898.89, a reduction of approximately 6.3%[29] - Total equity attributable to shareholders increased from 2,469,077,386.48 to 2,543,098,753.01, representing a growth of about 3%[29] Cash Flow - The net cash flow from operating activities was -¥20,120,816.00, a decline of 290.44% compared to the same period last year[6] - In Q1 2022, the cash inflow from operating activities was CNY 209,155,705.21, an increase from CNY 187,095,545.12 in Q1 2021, representing an increase of approximately 11.0%[37] - The net cash outflow from operating activities in Q1 2022 was CNY -20,120,816.00, compared to a net inflow of CNY 10,565,240.29 in Q1 2021[37] - The total cash outflow from operating activities in Q1 2022 was CNY 229,276,521.21, compared to CNY 176,530,304.83 in Q1 2021, reflecting an increase of approximately 29.8%[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,622[16] - The company reported a basic earnings per share of ¥0.19, down by 5.00% year-on-year[9] - Earnings per share for Q1 2022 were 0.19, slightly down from 0.20 in Q1 2021[35] Other Financial Metrics - The weighted average return on equity was 2.95%, a decrease of 3.20 percentage points year-on-year[9] - Cash and cash equivalents decreased to CNY 1.03 billion from CNY 1.74 billion, representing a decline of approximately 41%[24] - Accounts receivable increased to CNY 494.51 million from CNY 400.19 million, showing a growth of about 23%[24] - The company’s inventory decreased to CNY 155.36 million from CNY 159.68 million, a decline of approximately 3%[24] - The company’s other receivables increased to CNY 5.49 million from CNY 4.49 million, showing a growth of about 23%[24] - The company reported a decrease in employee compensation payable to CNY 25.02 million from CNY 46.27 million, a reduction of approximately 46%[27] - The company’s non-current assets totaled CNY 562.68 million, slightly up from CNY 551.89 million, reflecting an increase of about 2%[27] - Deferred income tax liabilities decreased from 5,402,815.13 to 5,210,334.06, a decline of approximately 3.5%[29] - The impact of exchange rate changes on cash and cash equivalents in Q1 2022 was CNY -218,020.84, contrasting with a positive impact of CNY 43,992.26 in Q1 2021[39] - The cash inflow from investment activities in Q1 2022 was CNY 904,215.33, down from CNY 2,203,041.10 in Q1 2021, a decrease of approximately 58.9%[39] - The net cash outflow from investment activities in Q1 2022 was CNY -690,328,193.10, compared to CNY -50,448,583.11 in Q1 2021, indicating a significant increase in outflows[39]

Financial Performance - The net profit attributable to the parent company for 2021 was RMB 322.36 million, representing a 15.50% cash dividend distribution from the net profit[4]. - The cash dividend distribution ratio for 2021 is below 30% of the net profit attributable to shareholders[7]. - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year increase of 15% compared to RMB 1.04 billion in 2020[20]. - The company reported a net profit of RMB 300 million for 2021, reflecting a net profit margin of 25%[20]. - The company achieved operating revenue of CNY 1,108,139,520.61 in 2021, representing a year-on-year increase of 18.18%[30]. - The net profit attributable to shareholders was CNY 322,360,736.79, up 13.76% compared to the previous year[30]. - The net cash flow from operating activities decreased by 36.79% to CNY 164,785,786.45, primarily due to increased R&D and marketing expenditures[30]. - The company reported a significant increase in non-operating income for 2021, primarily due to the receipt of policy rewards from the Beijing Urban Sub-center, amounting to 14,667,744.31[37]. - The company reported a total revenue of 27,780 million RMB, with a significant increase in R&D investment to 10,035.64 million RMB compared to the previous period[8]. - The company’s accounts receivable have been steadily increasing from 2018 to 2021, raising concerns about potential overdue payments and bad debts[109]. Research and Development - The company plans to continue increasing R&D investment to enhance its product pipeline and expand domestic and international sales teams[4]. - The company has allocated RMB 100 million for R&D in 2022, focusing on advanced materials and minimally invasive surgical technologies[20]. - R&D investment accounted for 9.46% of operating revenue, an increase of 1.72 percentage points compared to the previous year[30]. - The company is actively pursuing innovation in emerging technologies, with ongoing research and development efforts in new materials and manufacturing processes[75]. - The company received 173 new intellectual property rights this year, bringing the total to 283, including 15 invention patents and 153 utility model patents[86]. - The company is focusing on the development of joint surgery robots and sports medicine products in response to national joint procurement policies[88]. - The company’s R&D efforts are aimed at improving the longevity and performance of orthopedic implants, with a focus on innovative materials[91]. - The company’s testing center received CNAS laboratory accreditation, enhancing its research capabilities[86]. - The company is developing a series of hip joint products with a total investment of ¥81.46 million, of which ¥14.25 million was invested this period[91]. - The company is expanding its product line by integrating surgical robots with joint prosthetics, which is expected to significantly boost sales in the joint segment[11]. Market and Competitive Landscape - The orthopedic implant medical device market in China is projected to reach approximately 60.7 billion yuan by 2024, with a compound annual growth rate (CAGR) of about 14.51% from 2019 to 2024[60]. - The trauma segment accounted for the largest share of the orthopedic implant market in 2019, with a market share of 29.80%, while the spinal segment held 28.23% and the joint segment 27.77%[60]. - The market size for joint implant medical devices in China is expected to reach around 18.7 billion yuan by 2024, growing at a CAGR of approximately 6.87% from 2019 to 2024[60]. - The spinal implant medical device market is projected to reach about 17.1 billion yuan by 2024, with a CAGR of approximately 14.42% from 2019 to 2024[63]. - The trauma implant medical device market is expected to grow to around 17 billion yuan by 2024, with a CAGR of about 13.15% from 2019 to 2024[64]. - The top five companies in the orthopedic implant market in China held a combined market share of 42.71% in 2019, with Johnson & Johnson leading at 17.24%[68]. - The orthopedic market in China is experiencing significant growth, with foreign companies holding market shares of 67.88%, 66.71%, and 65.06% from 2017 to 2019, while domestic companies increased their shares from 32.12% to 34.94% during the same period[72]. - The company faces risks related to market competition, particularly from established international brands, and must adapt to changing sales models to maintain its market position[103]. - The company is navigating uncertainties in the import substitution process, facing challenges against international competitors with stronger resources and brand influence[108]. Product Development and Innovation - The company plans to expand its product line by introducing three new orthopedic implants in 2022, targeting a market share increase of 10% in the orthopedic sector[20]. - The company has successfully completed the clinical trials for its new PRP technology, which is expected to launch in Q3 2022[20]. - The company has introduced various 3D printing technologies, including EBM and MJF, to develop customized prosthetic products, enhancing production capabilities[73]. - The company is leading a project on porous tantalum bone repair materials, which has been approved as a key national R&D plan by the Ministry of Science and Technology[75]. - The development of biodegradable magnesium alloys is underway, focusing on their advantages in biocompatibility and mechanical properties, with the project currently in the design phase[75]. - The company has developed multiple core technologies in orthopedic implants, including hip, knee, shoulder, elbow, and spinal technologies[76]. - The company emphasizes the importance of advanced processing techniques to ensure product reliability and performance in clinical settings[76]. - The company’s core technologies are aligned with industry standards, ensuring competitive positioning in the orthopedic market[76]. - The company is committed to continuous innovation and development of new technologies to enhance patient outcomes and expand market reach[76]. - The company has advanced shoulder and elbow joint prosthesis design technologies, enhancing stability and longevity of implants[81]. Operational Strategies - The company plans to continue expanding its market presence and enhancing product competitiveness through increased R&D efforts[30]. - The traditional distribution model remains the primary sales strategy, with a focus on selecting distributors based on their qualifications and past performance[50]. - The implementation of the "two-invoice system" has led to a gradual increase in revenue from this model and the distribution model in recent years[50]. - The company has established a supplier evaluation mechanism to ensure that suppliers meet quality management standards and contractual obligations[44]. - The company engages in monthly reconciliations with suppliers and processes payments based on contractual agreements, allowing for credit terms with long-term partners[46]. - The company employs a unitized production management model for small-batch products, enhancing production efficiency and adaptability to product variety changes[47]. - The company has established a partnership with Syntellix Asia PTE. LTD. to market magnesium alloy orthopedic implant products, with a minimum purchase commitment over five years[52]. - The company is actively pursuing new materials such as porous tantalum and biodegradable magnesium alloys, which are expected to enhance its competitive edge[101]. - The company is investing in product innovation and R&D to maintain competitive advantages in a rapidly changing market environment[105]. - The company has implemented cost reduction strategies through increased production efficiency and reduced outsourcing costs[131]. Governance and Management - The company has a strong management team with nearly 30 years of experience in the medical device industry, led by Shi Chunbao and Yue Shujun[182]. - The company held 1 annual general meeting and 2 special meetings during the reporting period, ensuring compliance with legal requirements[169]. - The board of directors consists of 7 members, including 3 independent non-executive directors, ensuring compliance with relevant laws and regulations[169]. - The company maintains independence in finance, personnel, assets, and operations, ensuring no conflicts of interest with controlling shareholders[169]. - The total pre-tax remuneration for all directors and supervisors during the reporting period was 6.5708 million yuan[183]. - The company has established a comprehensive compensation management system that links employee bonuses and salary increases to individual and company performance[200]. - The company’s board of directors and remuneration committee review the remuneration policies for directors and supervisors[187]. - The company has not faced any penalties from securities regulatory authorities in the past three years[187]. - The company has not reported any changes in the positions of directors, supervisors, and senior management during the reporting period[187]. - The company plans to enhance its financing capabilities by leveraging capital market tools, which will support long-term sustainable development[164].